Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
Abstract Immune checkpoint inhibitors (ICIs) are able to reactivate the immune system, thereby enhancing the anti‐tumor effects. However, over‐activated T cells may induce immune‐related adverse events (irAEs). Hematological irAEs are rarely reported which mainly represent monolineage cytopenia or p...
Main Authors: | Junling Zhuang, Jianhua Du, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Wei Qiu, Xiaoyan Si, Li Zhang, Yue Li, Xiaowei Liu, Hanping Wang, Daobin Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-03-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13281 |
Similar Items
-
Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01) -
Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Jiaxin ZHOU, et al.
Published: (2019-10-01) -
Management of immune checkpoint inhibitor‐related rheumatic adverse events
by: Jiaxin Zhou, et al.
Published: (2020-01-01) -
Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01) -
Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)